Key Highlights
- Nura Bio closes $140M Series A financing to support clinical development.
- Shilpa Sambashivan, Ph.D., appointed as CEO following Phase 1 success of NB-4746.
- NB-4746 is a brain-penetrant SARM1 inhibitor with potential neuroprotective benefits.
- Phase 1 trial results show NB-4746 was well-tolerated and achieved target plasma exposure.
Source: Business Wire
Notable Quotes
- “Under Shilpa’s leadership, Nura Bio has successfully transitioned to a clinical-stage organization, making remarkable progress in identifying ways to translate complex biology into potential therapies.” — Tim Kutzkey, Ph.D., Managing Partner at The Column Group
- “I look forward to leading the company through this next phase as we prepare to test the SARM1 hypothesis in a patient population in 2025.” — Shilpa Sambashivan, Ph.D., CEO at Nura Bio
SoHC's Take
The successful closing of over $140M in Series A financing for Nura Bio underscores the increasing investor confidence in the company’s neuroprotective research and therapeutic pipeline. With NB-4746 progressing successfully through Phase 1 trials, Nura Bio is well-positioned to address significant unmet needs in the treatment of neurological diseases. Shilpa Sambashivan’s appointment as CEO is a strategic move, leveraging her deep scientific expertise and leadership to guide the company toward achieving its ambitious clinical milestones in the coming years.
Heading
In this five-part fireside chat, Dr. Jim Bonnette breaks down the real-world challenges holding health plans back—from fragmented vendor strategies ...
Key Highlights New Mountain Capital is backing SmarterDx at a billion-dollar valuation, according to a source familiar with the transaction.SmarterDx ...
Episode Details: Join us on the latest episode, hosted by Jared S. Taylor! Our Guest: Navin Gupta, CEO at Viventium & Hadas Nahon, ...
Episode Details Join us on the latest episode! Our Guest: Michael Oleksiw, CEO at Pleio. What you'll get out of ...
Key Highlights Babson Diagnostics partners with Sam’s Clubto expand BetterWay™ blood testingSeven Austin-area Sam’s Club pharmaciesto offer testing, starting with ...
Key Highlights Jeannette Bankes appointed President & CEO, Patient Care SolutionsEffective May 1, 2025, following Tom Westrick’s retirementBrings 30 years of ...
